Opus Genetics Enters Into Change in Control Bonus Agreements with Executive Officers

On April 1, 2026, Opus Genetics, Inc. entered into Change in Control Bonus Payment Agreements with its top executive leadership, including Dr. George Magrath (CEO), Robert Gagnon (CFO), Joseph Schachle (COO), and Dr. Ashwath Jayagopal (CSO). These agreements are designed to protect the executives from potential financial liabilities associated with a change in control of the company. Specifically, the agreements provide for a 'Gross-Up Payment' to reimburse the executives for any excise taxes incurred under Section 4999 of the Internal Revenue Code of 1986. The reimbursement covers the excise tax itself plus any additional federal, state, or local income and employment taxes resulting from the gross-up payment, ensuring the executives remain in the same after-tax position as if no excise tax had been imposed. All determinations regarding these payments will be made by an independent accounting or consulting firm. This move is intended to ensure executive focus and stability during potential corporate transitions.